Anti-Phosphatidic Acid IgG/IgM ELISA Kit

Name: Anti-Phosphatidic Acid IgG/IgM ELISA Kit
SKU: DEIA6106
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma

Species Reactivity

Human

Detection Method

Indirect ELISA

Intended Use

Anti-Phosphatidic Acid is an indirect solid phase enzyme immunoassay (ELISA) for the quantitative measurement of IgG and IgM class autoantibodies against phosphatidic acid in human serum or plasma.

Contents of Kit

1. Divisible microplate consisting of 12 modules of 8 wells each, coated with highly purified Phosphatidic Acid and saturated with beta-2-glycoprotein I
2. Combined calibrators with IgG and IgM class anti-phospholipid antibodies
3. Anti-phospholipid controls in a serum/buffer matrix
4. Sample buffer
5. Enzyme conjugate solution, containing polyclonal anti-human IgG; labelled with horseradish peroxidase
6. Enzyme conjugate solution, containing polyclonal anti-human IgM; labelled with horseradish peroxidase
7. TMB substrate solution
8. Stop solution
9. Wash solution

Storage

1. Store the kit at 2-8°C.
2. Keep microplate wells sealed in a dry bag with desiccants.
3. The reagents are stable until expiration of the kit.
4. Do not expose test reagents to heat, sun or strong light during storage and usage.
5. Diluted sample buffer and wash buffer are stable for at least 30 days when stored at 2-8°C. For more detailed information, please download the following document on our website.

Citations

Have you cited DEIA6106 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Gene expression profiling of ErbB receptor and ligand-dependent transcription

ONCOGENE

Authors: Amin, DN; Perkins, AS; Stern, DF

Abstract

Overexpression of ErbB2 and ErbB4 receptors in breast cancers may be accompanied by contrasting clinical outcomes. To investigate the molecular mechanisms contributing to these differences, we undertook a comparative study of gene expression regulated by the two receptors. Agonistic antibodies were employed to activate ErbB2 and ErbB4 in isolation from the other ErbBs in breast cancer cells. Gene expression pro. ling using a 16 755-gene oligonucleotide array was performed to identify transcriptional targets of receptor activation. Our results indicate that, in the same cell line, ErbB2 and ErbB4 activation influence gene transcription differentially. Although there are genes that are regulated by signaling from both receptors, there are also receptor-specific targets that are preferentially regulated by each receptor. We further show that two ligands acting via the same receptor homodimer may activate different subsets of genes. Many of the induced genes are hitherto unidentified targets of ErbB signaling. These include ErbB4 targets EPS15R, GATA4, and RAB2 and ErbB2-activated HRY/HES1 and PPAP2A. Targets of ErbB2 homodimer signaling may be especially important as markers in breast cancer, where ErbB2 homodimerization mediated by overexpression and ligand-independent activation is common.

Altered Expression of Sphingosine-1-Phosphate Metabolizing Enzymes in Oral Cancer Correlate With Clinicopathological Attributes

CANCER INVESTIGATION

Authors: Vishwakarma, Supriya; Agarwal, Rahul; Goel, Sudhir K.; Panday, Rajendra K.; Singh, Renu; Sukumaran, Ravi; Khare, Sarita; Kumar, Ashok

Abstract

We have determined the gene expression of sphingosine-1-phosphate (S1P) metabolizing enzymes (SphK1, SphK2, SGPL1, SGPP1, SGPP2, PPAP2A, PPAP2B, and PPAP2C) by quantitative real-time polymerase chain reaction in tumor tissues and adjacent normal tissues of 50 oral squamous cell carcinoma (OSCC) patients. Expression of SphK1 and SGPP1 genes was up-regulated significantly in 70% and 75% OSCC tumors respectively. Importantly, expression of SphK2 and PPAP2B was down-regulated in the tumor tissues of 70% OSCC patients. Expression of SphK2 and PPAP2B negatively correlated with tumor-node-metastasis (TNM) staging and tumor volume respectively. Furthermore, LPP1 is an independent predictor of TNM staging and lymph node ratio.